Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091052 | 0.90 | ADORA1 (0.82) | ADORA1KDM4EMAPTALDH1A1RAD52 | |
| SCHEMBL351992 | 0.90 | ADORA1 (0.82) | ADORA1KDM4EMAPTALDH1A1RAD52 | |
| SCHEMBL13739529 | 0.88 | ADORA1 (0.78) | ADORA1KDM4EMAPTALDH1A1RAD52 | |
| SCHEMBL27302182 | 0.87 | ADORA1 (0.77) | ADORA1KDM4EMAPTALDH1A1RAD52 | |
| SCHEMBL4065123 | 0.86 | MAPT (0.81) | ADORA1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL13037555 | 0.86 | ADORA1 (0.75) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL938054 | 0.85 | ADORA1 (1.00) | ADORA1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL135453 | 0.83 | KDM4E (0.83) | ADORA1KDM4EMAPTGAAMEN1 | |
| SCHEMBL17018772 | 0.83 | ADORA1 (0.71) | ADORA1KDM4EMAPTALDH1A1RAD52 | |
| SCHEMBL13739025 | 0.83 | ADORA1 (0.70) | ADORA1KDM4EMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940000-B1 | PROCESS FOR PREPARING METHYL ACETATE | DALIAN INST CHEMICAL PHYSICS CAS (CN) | 2017-10-18 | — | — | EP | disclosed |
| US-9440226-B2 | Method for preparing methyl acetate | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-13 | — | — | US | disclosed |
| EP-2940000-A1 | PROCESS FOR PREPARING METHYL ACETATE | Dalian Institute Of Chemical Physics, Chinese Academy of Sciences (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-20150298108-A1 | METHOD FOR PREPARING METHYL ACETATE | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-22 | — | — | US | disclosed |
| WO-2012148889-A1 | INHIBITORS OF HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150298108-A1 | METHOD FOR PREPARING METHYL ACETATE | EHMT2, EHMT1, DNMT1 | ADORA1 848/4885KDM4E 30/4885MAPT 2744/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | ADORA1 3978/4885KDM4E 1730/4885MAPT 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.